A dual-target Pt (IV) anticancer prodrug and its preparation method and use

Through the coordination and replacement of Pt(IV) complex with 3-bromopyruvate, a dual-target anti-cancer prodrug was generated, which solved the toxic side reactions and drug resistance of platinum drugs, and achieved efficient inhibition of tumor cells , especially in the glycolytic pathways.

CN116375769BActive Publication Date: 2024-12-03YUNNAN PRECIOUS METALS LAB CO LTD +1
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202310232456.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-03-10
Publication Date
2024-12-03
Estimated Expiration
2043-03-10

AI Technical Summary

Technical Problem

Existing platinum-based anti-cancer drugs such as cisplatin, carboplatin and oxaliplatin have toxic side effects and are prone to drug resistance problems. The Pt(II) complex is unstable in the internal environment and is difficult to effectively inhibit tumor cells. glycolysis pathway.

Method used

Using the Pt(IV) complex fac-[Pt(1R,2R-DACH)(OH)(3-bromophyruvate)3], the stability and target of the drug are increased by reaction with 3-bromopyruvate. , and intermediates are generated by axial oxidation of hydrogen oxide to form a dual-target anti-cancer prodrug, which is used to inhibit DNA replication and glycolysis pathways of tumor cells.

Benefits of technology

Improve the water solubility and stability of the drug, significantly improve the inhibitory activity of tumor cells, and reduce toxicity, especially in the inhibitory effect of drug-resistant tumor cells, with high anti-tumor activity and less toxicity .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004120946110000011
    Figure BDA0004120946110000011
  • Figure BDA0004120946110000021
    Figure BDA0004120946110000021
  • Figure BDA0004120946110000031
    Figure BDA0004120946110000031
Patent Text Reader

Abstract

The invention discloses a dual-target Pt(IV) anticancer prodrug, a preparation method and uses thereof. The chemical name is fac-[Pt(1R,2R-cyclohexanediamine)(hydroxyl)(3-bromopyruvate)3], i.e. fac-[Pt(1R,2R-DACH)(OH)(3-bromopyruvate)3], which is a prodrug of oxaliplatin. The molecule contains three 3-bromopyruvic acid (glycolysis inhibitor) ligands, can simultaneously inhibit the replication and glycolysis pathway of tumor cell DNA, and has two action targets. Its synthesis is to use cis-[Pt(1R,2R-DACH)I2] or cis-[Pt(1R,2R-DACH)Cl2] as a starting material, after being hydrolyzed with silver sulfate, react with an alkali metal hydroxide to obtain a cis-[Pt(1R,2R-DACH)(OH)2] solution, then axially oxidize with hydrogen peroxide to generate an intermediate cis-[Pt(1R,2R-DACH)(OH)4]·H2O, and finally neutralize with 3 times the molar amount of 3-bromopyruvic acid to obtain a target complex. The Pt(IV) anticancer prodrug of the present invention has good water solubility and aqueous solution stability, strong antitumor effect, low toxicity, low cross-resistance with oxaliplatin, and is used for chemotherapy of malignant tumors.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a dual-target Pt(IV) anticancer prodrug and a preparation method and use thereof. The Pt(IV) anticancer prodrug is a Pt(IV) complex, and its chemical formula is fac-[Pt(1R,2R-cyclohexanediamine)(hydroxyl)(3-bromopyruvate)3], i.e., fac-[Pt(1R,2R-DACH)(OH)(3-bromopyruvate)3], which is a prodrug of oxaliplatin and contains three 3-bromopyruvic acid (glycolysis inhibitor, 3-bromopyruvic acid) ligands. The Pt(IV) anticancer prodrug of the present invention can simultaneously inhibit the replication and glycolysis pathway of tumor cell DNA, has two action targets, has good water solubility, high anti-tumor activity, can be used for chemotherapy of malignant tumors, and belongs to the field of biopharmaceuticals. Background Art

[0002] Malignant tumors are the second leading cause of death after cardiovascular and cerebrovascular diseases. Although targeted therapy and immunotherapy have emerged in recent years, which have greatly improved the prognosis of clinical tumor treatment, surgery, radiotherapy and chemotherapy are still the indispensable basic therapies for clinical treatment of malignant tumors. Chemotherapy, in particular, has unique advantages in targeting the heterogeneity and rapid proliferation of tumor cells. Combined with targeted therapy and immunotherapy, it can make up for the shortcomings of targeted and immunotherapy in this regard. The basis of chemotherapy is chemotherapeutic drugs. Platinum anticancer drugs represented by cisplatin (DDP), carboplatin (CBP) and oxaliplatin (OXP) are a very important class of chemotherapeutic drugs. Their target is cancer cell DNA, with strong anticancer activity and unique mechanism of action. They have synergistic anticancer effects with most natural drugs (such as paclitaxel), targeted drugs (such as gefitinib, trastuzumab), and immunotherapy drugs (such as PD-1 / PD-L1 immunosuppressants pembrolizumab / atezolizumab), and are widely used in the clinical treatment of common and multiple malignant tumors. According to the latest statistics, more than 50% of chemotherapy regimens are based on platinum anticancer drugs or are combined with platinum anticancer drugs. However, there are still two major defects in the clinical application of platinum anticancer drugs: toxicity and side effects and the easy emergence of drug resistance. Therefore, the development of new platinum drugs with high anticancer activity, low toxicity and low cross-resistance with existing drugs still has important clinical value.

[0003] The chemical structures of cisplatin, carboplatin and oxaliplatin are:

[0004]

[0005] The platinum drugs currently used in clinical practice, including cisplatin, carboplatin and oxaliplatin, are all Pt(Ⅱ) complexes. 8 Valence electron configuration, using d 2 sp 3Hybridization forms a four-coordinate planar configuration, and the coordination substitution reaction kinetics are relatively active. Before reaching the cancer cell DNA target, it is easy to react with the biological molecules in the blood or intercellular fluid that we do not want, producing toxic side effects and also degrading some drugs. The Pt(Ⅱ) complex forms a six-coordinate octahedral Pt(Ⅳ) complex after axial oxidation. The general structural formula is cis, trans, cis-[Pt(Ⅳ)A2Y2X2] (where A is the pharmacophore, Y is the axial ligand, and X is the leaving group). The reaction kinetics are inert, and the reaction rate with biological macromolecules is significantly reduced. It can maintain relative stability in the in vivo environment and has low toxicity. In addition, tumor tissue belongs to a reducing microenvironment, and the concentrations of glutathione and vitamin C are significantly higher than those of normal cells, which can reduce Pt(Ⅳ) to the corresponding Pt(Ⅱ) anticancer drug cis-[Pt(II)A2X2]. Therefore, Pt(IV) complexes can be regarded as prodrugs of Pt(II) anticancer drugs, providing an effective way for tumor-targeted delivery of Pt(II) anticancer drugs. In addition, the selection of appropriate axial ligand Y can also adjust the water solubility and lipid solubility of Pt(IV) complexes, increase the target sites to improve anticancer activity, etc. Therefore, Pt(IV) prodrugs are one of the hot research directions of platinum anticancer drugs in recent years.

[0006]

[0007] The energy supply of human cells mainly comes from glucose, and there are two pathways: mitochondrial oxidative phosphorylation and glycolysis. Normal cells mainly rely on mitochondrial oxidative phosphorylation to obtain energy; unlike normal cells, tumor cells lack metabolic flexibility and mainly supply themselves with energy through the glycolysis pathway. This is an adaptive response to intermittent hypoxia. Even under normal oxygen concentrations, this energy supply mode is maintained, which is the so-called Warburg effect. However, the energy produced by the glycolysis process is limited. Therefore, in order to maintain rapid proliferation and other activities, tumor cells will accelerate the body's uptake and metabolism of sugar. This obvious feature makes the glycolysis pathway an important target for anti-tumor. 3-bromopyruvate is an organic carboxylic acid small molecule that can inhibit the glycolysis pathway by inhibiting the activity of hexokinase II (the first rate-limiting enzyme of glycolysis), resulting in the inability of tumor cells to absorb energy and die, while having no effect on surrounding normal tissues and cells; moreover, 3-bromopyruvate can also overcome the multidrug resistance of tumors and enhance the activity of anticancer drugs such as platinum anticancer drugs. However, 3-bromopyruvate is relatively unstable and will quickly degrade after entering the human body, with no obvious anti-tumor effect. Therefore, the stability of 3-bromopyruvate becomes the main limiting factor affecting its anti-tumor effect. Summary of the invention

[0008] The technical problem solved by the present invention is to introduce 3-bromopyruvic acid into the Pt(IV) prodrug molecule through coordination substitution reaction with the axial and radial hydroxyl groups of Pt(IV), so as to increase the action target of the Pt(IV) prodrug and improve the stability of 3-bromopyruvic acid.

[0009] The present invention uses cis-[PtA2I2] or cis-[PtA2Cl2] as a starting material, and performs a hydrolysis reaction with an equimolar amount of AgSO4 to generate cis-[PtA2(OH2)2](SO4), and then reacts with an equimolar amount of alkali metal hydroxide to convert into a cis-[PtA2(OH)2] solution, and then undergoes axial oxidation with hydrogen peroxide to obtain an intermediate cis-[PtA2(OH)4]·H2O. The synthetic route of the dual-target Pt(IV) anticancer prodrug can be expressed as follows:

[0010]

[0011] The above synthetic route is suitable for 2A being 2NH3, ethylenediamine, 1,2-propylenediamine, 1,3-propylenediamine, 1R, 2R-DACH and other ammonia / amine ligands and mixed amines. Finally, the intermediate is neutralized with 3-bromopyruvic acid to form a Pt(IV) complex with the following chemical formula:

[0012] (1)fac-[Pt(IV)A2(OH)(3-bromopyruvate)3];

[0013] (2)cis-[Pt(IV)A2(3-bromopyruvate)4].

[0014] After many studies and experiments, the inventors successfully synthesized a Pt(IV) complex containing three molecules of 3-bromopyruvic acid, fac-[Pt(1R,2R-DACH)(OH)(3-bromopyruvate)3] (code: BrPt-4), which is a prodrug of oxaliplatin with a yield of about 82%. Its chemical structure is:

[0015]

[0016] A method for preparing a dual-target Pt(IV) anticancer prodrug comprises the following steps:

[0017] Step (1): cis-[Pt(1R,2R-DACH)I2] or cis-[Pt(1R,2R-DACH)Cl2] and an equimolar amount of Ag2SO4 are reacted in an aqueous solution in the dark with stirring for 6 hours at 45-60°C, and the silver iodide or silver chloride precipitate is removed by filtration to obtain a cis-[Pt(1R,2R-DACH)(OH2)2](SO4) solution;

[0018] Step (2): stirring and reacting cis-[Pt(1R,2R-DACH)(OH2)2](SO4) and an equimolar amount of alkali metal hydroxide for 1 to 4 hours at 15 to 30° C., filtering and removing the alkali metal sulfate (MSO4) precipitate to obtain a cis-[Pt(1R,2R-DACH)(OH)2] solution;

[0019] Step (3): at 30-50° C., add excess hydrogen peroxide to the cis-[Pt(1R, 2R-DACH)(OH)2] solution, stir and react for 4 hours, evaporate the obtained solution under reduced pressure to a minimum volume, add a large amount of glacial acetone for reverse analysis, filter, dry, and then recrystallize from a water-acetone mixed solvent to obtain the intermediate cis-[Pt(1R, 2R-DACH)(OH)4]·H2O;

[0020] Step (4): cis-[Pt(1R,2R-DACH)(OH)4]·H2O and 3 times the molar amount of 3-bromopyruvate are stirred in an aqueous solution at 30-40°C for 48-72 hours. The obtained solution is freeze-dried, filtered, washed with ether, dried, and then recrystallized from methanol to obtain the target complex fac-[Pt(1R,2R-DACH)(OH)(3-bromopyruvate)3].

[0021] Furthermore, the alkali metal hydroxide described in step (2) is any one of strontium hydroxide, calcium hydroxide and barium hydroxide.

[0022] Furthermore, in step (3), the molar ratio of cis-[Pt(1R, 2R-DACH)(OH)2]:H2O2 is 1:10-25.

[0023] The reaction process is as follows:

[0024]

[0025]

[0026]

[0027]

[0028] The inventors found in the synthesis experiment that in the aqueous solution system used for synthesis, even if the amount of 3-bromopyruvic acid was increased to 6 times the calculated amount, 4 3-bromopyruvic acid ligands could not be introduced at the same time, and the structure thereof is:

[0029]

[0030] The isolated product is still BrPt-4 containing three 3-bromopyruvate groups. This may be because when the three hydroxyl groups in cis-[Pt(IV)A2(OH)4]·H2O are replaced by 3-bromopyruvate, the pK a The value is not enough to replace the fourth hydroxyl group in the molecule.

[0031] BrPt-4 is a prodrug of oxaliplatin with a water solubility of 12.1 mg / mL. 1 The change of H-NMR over time shows that after 72 hours at room temperature, 1 There is no obvious change in H-NMR, so BrPt-4 has good stability in aqueous solution and meets the conditions required for the drug formation of platinum complexes.

[0032] By using the MTT method, it was found that the Pt(IV) complex BrPt-4 of the present invention has high inhibitory activity on the proliferation of human non-small cell lung cancer cell line (A549), human ovarian cancer cell line (SKOV3), human gastric cancer cell line (MKN-28), human colon cancer cell line (HCT116), and human liver cancer cell line (HepG2), indicating that BrPt-4 has high in vitro anti-cancer cell proliferation activity. Moreover, most importantly, the inhibitory activity of BrPt-4 on the proliferation of human non-small cell lung cancer cell line (A549 / OXP) resistant to oxaliplatin is significantly higher than that of oxaliplatin, indicating that BrPt-4 has considerable resistance to cancer cell resistance.

[0033] In the in vivo model of mouse transplanted tumor S180, the tumor inhibition rate of BrPt-4 after intraperitoneal injection was significantly higher than that of oxaliplatin. Judging from the changes in mouse body weight, thymus and spleen indexes, liver and kidney function indicators, blood routine and bone marrow hyperplasia after administration, except for the slightly larger difference in mouse body weight before and after administration, other toxicity indicators of BrPt-4 were significantly lower than those of oxaliplatin, indicating that BrPt-4 has high anti-tumor activity and low toxicity.

[0034] According to the results reported in domestic and foreign literature, the anti-tumor activity of Pt(Ⅳ) complexes is generally inferior to that of the corresponding Pt(Ⅱ) drugs, which is probably due to the inability of Pt(Ⅳ) to be fully reduced to Pt(Ⅱ). The anti-tumor activity of BrPt-4 is higher than that of oxaliplatin, which may be partly due to the anti-tumor effect of 3-bromopyruvic acid (3-BrPA), that is, BrPt-4 has two targets, and its anti-tumor mechanism can be expressed as:

[0035]

[0036] In addition to inhibiting the replication of tumor cell DNA, the Pt(IV) complex BrPt-4 of the present invention can also obtain additional anti-tumor efficacy by inhibiting the glycolysis pathway of tumor cells.

[0037] In summary, the Pt(IV) complex BrPt-4 of the present invention has good water solubility, high stability, high anti-tumor activity and low toxicity, and can be used as a prodrug of oxaliplatin for the treatment of malignant tumors (such as lung cancer, ovarian cancer, gastric cancer, colon cancer and liver cancer, etc.). BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Figure 1 : The chemical structural formula of the Pt(IV) complex BrPt-4 of the present invention.

[0039] Figure 2 : Schematic diagram of the effect of intraperitoneal (ip) injection of the test compound on the bone marrow of tumor-bearing mice. DETAILED DESCRIPTION

[0040] Example 1: Synthesis of intermediate cis-[Pt(1R,2R-DACH)(OH)4]·H2O

[0041] Add cis-[Pt(1R, 2R-DACH)I2](6.26 g, 11.12 mmol) or cis-[Pt(1R, 2R-DACH)Cl2](4.23 g, 11.12 mmol) into 60 mL of water and stir to form a uniform paste. Add an aqueous solution (110 mL) of silver sulfate (3.40 g, 10.90 mmol) and stir at 45-60 °C in the dark for 6 hours. After checking that the reaction has reached the endpoint, filter and wash with water 3 times to obtain a light yellow clear filtrate. Add an equimolar amount of alkali gold The reaction mixture was stirred at 15-30°C in the dark for 1-4 hours, filtered to obtain a colorless clear filtrate, the filtrate was placed in a water bath at 30-50°C, 30 wt% hydrogen peroxide (25.21-63.01 g) was added dropwise, and the reaction was continued with stirring for 4 hours. The reaction solution was evaporated to a minimum volume under reduced pressure to obtain a light yellow oil, and a large amount of glacial acetone was added for reverse analysis to precipitate a white to light yellow solid, which was filtered, washed twice with glacial acetone, and dried in vacuo for 8 hours. The crude product was recrystallized from a water-acetone mixed solvent to obtain 3.80 g cis-[Pt(1R,2R-DACH)(OH)4]·H2O with a yield of 86.26%.

[0042] Structural characteristic parameters: <1> Elemental analysis: Measured values: Pt 49.12%, C 17.96%, H 5.88%, N 6.81% (calculated values: Pt 49.40%, C 18.22%, H 5.06%, N 7.09%).

[0043] Example 2: Synthesis of the target complex fac-[Pt(1R,2R-DACH)(OH)(3-bromopyruvate)3(BrPt-4)

[0044] Dissolve cis-[Pt(1R,2R-DACH)(OH)4]·H2O (1.01 g, 2.56 mmol) in 10 mL of water, add 3-bromopyruvic acid (1.35 g, 8.08 mmol) in water (5 mL), and stir at 30-40°C for 48-72 hours. During the reaction, the solution gradually precipitates a brown-yellow solid from a clear solution. After the reaction, the reaction solution is freeze-dried, filtered, washed with ether three times, and vacuum-dried for 8 hours. The obtained brown-yellow solid is then purified by methanol recrystallization to obtain 1.71 g of the product with a yield of 81.12%.

[0045] Structural characteristic parameters:

[0046] (1) Elemental analysis

[0047] Measured values ​​Pt 23.38%, C 21.47%, H 3.08%, N 3.01% (calculated values ​​Pt 23.66%, C 21.84%, H 2.55%, N 3.40%);

[0048] (2) 1 H NMR(500MHz,DMSO-d6)δ6.31-5.49(m,4H,2NH2),3.33(s,H2O),2.50(p,J=1.8Hz, DMSO),2.35(d,J=15.8Hz,2H,2CH-cyclohexyl),1.98(d,J=12.6Hz,2H,CH2-ax-3- BrPA),1.89(t,J=13.6Hz,4H,2CH2-eq-3-BrPA),1.51(s,2H,CH2-cyclohexyl),1.26(d,J=31.1Hz,4H,2CH2-cyclohexyl),1.02(t,J=10.6Hz,2H,CH2-cyclohexyl);

[0049] (3)IR(KBr,cm -1 ): 3435(m), 3202(m), 1687(s), 1322(s), 573(w), 513(w), 440(w);

[0050] (4) ESI-MS: 825 [M+H] + .

[0051] Example 3: In vitro inhibitory activity of the Pt(IV) complex BrPt-4 of the present invention on tumor cell proliferation

[0052] The positive control sample oxaliplatin (batch number: L20200428) was purchased from Kunming Guiyan Pharmaceutical Co., Ltd.; the tumor cell line was purchased from the Cell Bank of Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences.

[0053] The MTT method was used to detect the effects of compound BrPt-4 and oxaliplatin (OXP) on cell proliferation. Cells in the logarithmic growth phase, including human non-small cell lung cancer cell line (A549) and its oxaliplatin-resistant strain (A549 / OXP), human ovarian cancer cell line (SKOV3), human gastric cancer cell line (MKN-28), human colon cancer cell line (HCT116), human liver cancer cell line (HepG2) and human normal liver cells (L02), were routinely digested to prepare single cell suspension and counted, and the cell suspension was adjusted to a certain concentration, inoculated in a 96-well culture plate, 90μL / well, and cultured in a 37℃, 5% CO2 saturated humidity incubator for 24h. After the cells adhered to the wall, different concentrations of the test drugs were added. All compounds were prepared with glucose injection (5% GS). Five different test concentrations were set according to different cells, and 4 parallel wells were set for each concentration, 10μL / well. After adding the drug, the cells were placed in the incubator for 48 hours, and then 20 μL of MTT (5 mg / ml) was added to each well. After 4 hours of incubation, the supernatant was aspirated, and then 100 μL of DMSO was added to each well to dissolve the reduced formazan. The OD value of each well was measured at 570 nm and 630 nm with an enzyme marker, and the inhibition rate was calculated. According to the inhibition rate of each concentration, the half inhibition concentration IC was calculated using SPSS software. 50 , the results are shown in Table 1.

[0054] Table 1. Effects of the tested compounds on the proliferation of different cell lines

[0055]

[0056] As shown in the results in Table 1, the invented compound BrPt-4 has a slightly lower inhibitory activity on the proliferation of human non-small cell lung cancer cell line (A549) than oxaliplatin, but has a high inhibitory activity on the proliferation of human non-small cell lung cancer cell line (A549 / OXP) resistant to oxaliplatin, human ovarian cancer cell line (SKOV3), human gastric cancer cell line (MKN-28), human colon cancer cell line (HCT116) and human liver cancer cell line (HepG2), IC 50 In particular, the inhibitory activity on the proliferation of the lung cancer cell line A549 / OXP resistant to oxaliplatin is significantly higher than that of oxaliplatin, indicating that the invented compound has considerable resistance to tumor cell resistance.

[0057] During the test, we also set up a normal human cell line (L02) for comparison to evaluate the toxicity of the test compound to normal cells. The results showed that the inhibitory concentration of BrPt-4 on the growth of the normal cell line was IC 50 It is greater than the corresponding oxaliplatin, indicating that BrPt-4 has a certain selectivity for tumor cells.

[0058] Example 4: In vivo tumor inhibition and preliminary toxicity evaluation of the Pt(IV) complex BrPt-4 administered by intraperitoneal injection

[0059] Kunming mice (KM), 22-25 g, female, were purchased from Hunan Slake Experimental Animal Co., Ltd.; mouse sarcoma S180 tumor strain was obtained from Shanghai Institute of Materia Medica, Chinese Academy of Sciences; positive control drug oxaliplatin (lot number: L20200428) was purchased from Kunming Guiyan Pharmaceutical Co., Ltd. BrPt-4 and oxaliplatin were prepared with 5% GS to the required concentration.

[0060] Take the well-growing S180 cells of ascites-type mice 5 to 8 days after inoculation, adjust the cell concentration to 1.0×10 7 / mL, inoculated subcutaneously in the right axilla of mice, 0.2mL / mouse, and randomly divided into 3 groups 24 hours after inoculation. The solvent, oxaliplatin and BrPt-4 were given by intraperitoneal injection (ip) once a day for 13 consecutive days. The dosage was based on the half effective dose (ED50) of oxaliplatin for inhibiting S180 in mice reported in the literature. 50 ) and the preliminary test results of this study, 7.6μmol / kg was selected. The mice were killed 24h after the last administration, and fasted and deprived of water for 12h before the sacrifice. The tumors were taken out and weighed, and the tumor inhibition rate was calculated = (average tumor weight of the control group - average tumor weight of the treatment group / average tumor weight of the control group × 100%). The data were expressed as mean ± standard deviation, and the P value was processed and analyzed using SPSS statistical software. The results are shown in Table 2. At the same time, the effects of the compound on body weight, important organs and blood indicators after administration were investigated to evaluate its preliminary toxicity.

[0061] 1. Overall in vivo anti-tumor effect

[0062] The experimental results are shown in Table 2. Compared with the vehicle group, oxaliplatin and BrPt-4 had significant tumor inhibition effects, with inhibition rates of 67.81% and 83.14%, respectively. However, the weight gain of mice after administration was also affected, which was statistically significant compared with the vehicle group, indicating toxic reactions. Considering the tumor inhibition rate and the weight change of mice after administration, BrPt-4 had better efficacy than oxaliplatin at equimolar doses.

[0063] Table 2. Effects of intraperitoneal injection (ip) of the test compounds on the growth of S180 transplanted tumors in mice

[0064]

[0065] Note: Compared with the vehicle control group: *, P<0.05; **, P<0.01; ***, P<0.001

[0066] 2. Effects of drug administration on important organs and blood indicators

[0067] The thymus and spleen are important immune organs and the most common toxic target organs of cytotoxic anticancer drugs. The liver and kidneys are the main organs for drug metabolism and the main toxic targets of platinum drugs. The results in Table 3 show that compared with the solvent control group, the weight of the thymus and spleen of the mice in the drug-treated group was significantly reduced, indicating that both oxaliplatin and BrPt-4 have immunosuppressive effects, but from the degree of reduction of the two compounds, oxaliplatin has a stronger immunosuppressive effect than BrPt-4. At a dose of 7.6 μmol / kg, oxaliplatin and BrPt-4 had little effect on the liver and kidney coefficients of mice.

[0068] Table 3. Effects of intraperitoneal injection (ip) of the test compounds on the weights of spleen, thymus, liver and kidney in tumor-bearing mice

[0069]

[0070] Note: Compared with the vehicle group: *, P<0.05; **, P<0.01; ***, P<0.001.

[0071] Alanine aminotransferase ALT and aspartate aminotransferase AST are liver function indicators that reflect whether liver cells are damaged and the severity of damage. They are present in liver cells. When the liver cell membrane is damaged or the cells are necrotic, these enzymes enter the serum and increase; serum creatinine CREA concentration can accurately reflect the degree of damage to glomerular filtration function to a certain extent. When renal function is normal, the creatinine excretion rate is constant. When the renal parenchyma is damaged, the glomerular filtration rate will decrease. When the filtration rate decreases to a certain extent, the blood creatinine concentration will rise sharply; urea nitrogen BUN is a metabolic product of human protein, which is mainly excreted from the body with urine through glomerular filtration. When the renal parenchyma is damaged, the glomerular filtration rate decreases, causing the urea nitrogen concentration in the blood to increase. Therefore, by measuring urea nitrogen, the glomerular filtration function can be understood. Table 4 shows the changes in liver and kidney function indicators of S180 mice after intraperitoneal injection (ip) of oxaliplatin and BrPt-4. Compared with the vehicle group, BrPt-4 had little effect on liver and kidney function, while the AST in the oxaliplatin group increased and was statistically significant, suggesting that it had an effect on liver function. Oxaliplatin also had little effect on kidney function, and this result was consistent with reports at home and abroad.

[0072] Table 4. Effects of intraperitoneal injection (ip) of the test compounds on liver and kidney function in tumor-bearing mice

[0073]

[0074] Note: Compared with the vehicle control group: *, P<0.05; **, P<0.01.

[0075] Bone marrow suppression is also the most common toxicity of platinum drugs, often the dose-limiting toxicity, and the main factor causing death in mice during acute toxicity tests. Bone marrow suppression leads to a decrease in the number of blood cells, among which platelets (PLT) and white blood cells (WBC) decrease particularly significantly. The results in Table 5 show that after tumor-bearing mice were given oxaliplatin and BrPt-4, WBC, PLT, and RBC (red blood cells) all showed a decreasing trend to varying degrees, among which the decrease in the oxaliplatin group was particularly obvious, and there was a significant difference compared with the vehicle group, indicating that oxaliplatin bone marrow suppression was more serious than BrPt-4.

[0076] Further mouse sternum bone marrow smear test showed (such as Figure 2 As shown in the figure, compared with the vehicle control group, the bone marrow proliferation of mice in the oxaliplatin group was extremely reduced, while the bone marrow proliferation of the BrPt-4 group was active, indicating that the bone marrow toxicity of oxaliplatin is greater than that of BrPt-4 of the present invention.

[0077] Table 5. Effects of intraperitoneal injection (ip) of the test compounds on blood routine in tumor-bearing mice

[0078]

[0079] Note: Compared with the negative control group: *, P<0.05; **, P<0.01; ***, P<0.001.

Claims

1. A dual-target Pt(IV) anticancer prodrug, characterized in that: The chemical name of the Pt(IV) anticancer prodrug is fac-[Pt(1R,2R-cyclohexanediamine)(hydroxy)(3-bromopyruvate)3], and the molecule contains three glycolysis inhibitor 3-bromopyruvate ligands, and the chemical structure is:

2. A method for preparing a dual-target Pt (IV) anticancer prodrug according to claim 1, characterized in that: The following steps are involved: Step (1): cis-[Pt(1R,2R-DACH)I2] or cis-[Pt(1R,2R-DACH)Cl2] and an equimolar amount of Ag2SO4 are reacted in an aqueous solution in the dark with stirring at 45 to 60°C, and the silver iodide or silver chloride precipitate is removed by filtration to obtain a cis-[Pt(1R,2R-DACH)(OH2)2](SO4) solution; Step (2): stirring and reacting cis-[Pt(1R,2R-DACH)(OH2)2](SO4) and an equimolar amount of alkali metal hydroxide at 15-30° C., filtering and removing the alkali metal sulfate precipitate, and obtaining a cis-[Pt(1R,2R-DACH)(OH)2] solution; Step (3): adding excess hydrogen peroxide to a cis-[Pt(1R,2R-DACH)(OH)2] solution at 30-50°C, stirring for reaction, subjecting the obtained solution to vacuum rotary evaporation, adding glacial acetone for reverse analysis, filtering, drying, and then recrystallizing from a water-acetone mixed solvent to obtain an intermediate cis-[Pt(1R,2R-DACH)(OH)4]·H2O; Step (4): cis-[Pt(1R,2R-DACH)(OH)4]·H2O and 3 times the molar amount of 3-bromopyruvic acid are stirred and reacted in an aqueous solution at 30-40°C. The obtained solution is freeze-dried, filtered, washed with ether, dried, and then recrystallized from methanol to obtain the target complex fac-[Pt(1R,2R-DACH)(OH)(3-bromopyruvate)3].

3. The preparation method according to claim 2, characterized in that: The alkali metal hydroxide described in step (2) is any one of strontium hydroxide, calcium hydroxide and barium hydroxide.

4. The preparation method according to claim 2, characterized in that: The molar ratio of cis-[Pt(1R,2R-DACH)(OH)2]:H2O2 in step (3) is 1:10-25.

5. The preparation method according to any one of claims 2 to 4, characterized in that: In step (1), the reaction was stirred in the dark for 6 hours.

6. The preparation method according to any one of claims 2 to 4, characterized in that: In step (2), the reaction is stirred for 1 to 4 hours.

7. The preparation method according to any one of claims 2 to 4, characterized in that: In step (3), the reaction was stirred for 4 hours.

8. The preparation method according to any one of claims 2 to 4, characterized in that: In step (4), the reaction is stirred for 48 to 72 hours.

9. Use of a dual-target Pt(IV) anticancer prodrug according to claim 1 in the preparation of an anti-tumor drug for clinical chemotherapy of malignant tumors.

10. The use according to claim 9, characterized in that The malignant tumors include lung cancer, ovarian cancer, stomach cancer, colon cancer and liver cancer.

Citation Information

Patent Citations

  • Antitumour and antiparasitic platinum complexes - contg. 1,2-di:amino-cyclohexane ligand

    BE898614A

  • Compositions and methods for the treatment of cancer

    CN102387801A